Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
2.
Turk J Gastroenterol ; 34(1): 62-72, 2023 01.
Article in English | MEDLINE | ID: mdl-36098363

ABSTRACT

BACKGROUND: Relevant studies have indicated that hepatic mast cells may have potential roles in the progression of cholestasis and cholestasis-induced itch. We aimed to compare the effects of cromolyn sodium and other medications on cholestatic pruritus, serum biochemistry, histamine, total bile acids, autotaxin, liver histopathology, and mast cell distribution in tissues in an experimental cholestasis model conducted by bile duct ligation. METHODS: Rats received the determined treatment consecutively for 10 days in addition to bile duct ligation. On the 5th and 10th days of the experiment, the rats' itching behaviors were observed for 5 minutes. After 10 days, blood and tissue samples were taken. RESULTS: Significant decreases in serum histamine and autotaxin levels, plasma total bile acids, total bilirubin, and biliary enzymes were reported only in cromolyn sodium-treated rats compared to the control group. In immunohistochemistry of the liver samples, the peribiliary mast cells stained positive for autotaxin. Except for bile duct infarctus, all histopathological findings of cholestasis significantly improved only in cromolyn sodium-treated and sertraline-treated rats. The liver and peritoneal mast cells significantly decreased only in cromolyn sodium-treated rats compared to the control group. On the 10th day of the experiment, the mean duration of itching was significantly lower in all groups, except for naloxone- and ondansetron-treated rats. CONCLUSION: Cromolyn sodium has promising antipruritic efficacy and provides biochemical and histopathological recovery of the relevant parameters of cholestasis induced by bile duct ligation. For the first time in the literature, we showed that peribiliary mast cells can produce autotaxin, which is a very important pruritogenic signal in the setting of cholestasis.


Subject(s)
Cholestasis , Cromolyn Sodium , Rats , Animals , Cromolyn Sodium/pharmacology , Cromolyn Sodium/therapeutic use , Mast Cell Stabilizers/therapeutic use , Histamine/therapeutic use , Cholestasis/complications , Cholestasis/drug therapy , Liver/pathology , Pruritus/drug therapy , Pruritus/etiology , Pruritus/pathology , Ligation
3.
J Allergy Clin Immunol ; 148(3): 822-834, 2021 09.
Article in English | MEDLINE | ID: mdl-33819510

ABSTRACT

BACKGROUND: Vernal keratoconjunctivitis (VKC) is a severe type of allergic conjunctivitis for which treatment strategies are still under debate. OBJECTIVES: This study sought to conduct a systematic review and meta-analysis to evaluate the efficacy of medical treatments for VKC. METHODS: The PubMed, Cochrane Library, Embase, and ScienceDirect databases were searched to assess the efficacy of treatments for VKC. Random-effect meta-analyses on changes in clinical scores of symptoms and signs between baseline and after treatment, stratified on treatment classes, were computed. Meta-regressions were searched for potential influencing parameters. RESULTS: Included were 45 studies (27 randomized controlled trials and 18 prospective cohort studies), 1749 patients (78% were men; mean age, 11.2 years), and 12 different treatment classes. Mast cell stabilizers (MCSs; usually considered as first-line therapy), cyclosporine, and tacrolimus were the most studied drugs (in three-quarters of studies). Overall, all clinical scores improved. Total symptom and sign score decreased for MCSs (effect size, -3.19; 95% CI, -4.26 to -2.13), cyclosporine (effect size, -2.06; 95% CI, -2.72 to -1.40), and tacrolimus (effect size, -2.39; 95% CI, -3.36 to -1.43). No significant differences were shown depending on treatment classes, concentration, age, sex, baseline activity scores, and atopy. Sensitivity analyses demonstrated similar results. CONCLUSIONS: This study confirms the efficacy of MCSs in the treatment of VKC. Efficacy of cyclosporine and tacrolimus did not differ, suggesting that tacrolimus is a good alternative to cyclosporine for severe cases of VKC. Further studies are needed to compare other drugs and their precise place in treatment strategy.


Subject(s)
Conjunctivitis, Allergic/drug therapy , Adrenal Cortex Hormones/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Mast Cell Stabilizers/therapeutic use , Prospective Studies , Randomized Controlled Trials as Topic
4.
Curr Opin Allergy Clin Immunol ; 20(5): 507-515, 2020 10.
Article in English | MEDLINE | ID: mdl-32739978

ABSTRACT

PURPOSE OF REVIEW: The rising global burden of allergic diseases, particularly in the pediatric population, is of serious concern. Ocular allergy is one of the most common ocular pathologies met in clinical practice. A large proportion of children and adolescents suffer from allergic eye diseases (AEDs), which affect their quality of life. The available treatments and surgical modalities have their limitations and side effects. Therefore, the development of novel and alternate strategies is the need of the hour and requires a timely review of currently available knowledge. RECENT FINDINGS: The current review covers the incidence and prevalence of AEDs, factors influencing occurrence and severity of AED (age, sex, socioeconomic status etc.), underlying mechanisms, role of allergy testing and immunotherapy in children, development of diagnostic markers and novel therapies including cells and molecules. SUMMARY: Understanding the demographics, clinical patterns and risk factors of AED can help formulate appropriate preventive and therapeutic strategies for the effective management of this common cause of ocular morbidity. The future therapeutics for AED seems to rely primarily on cells (mesenchymal stem cells, Tregs, mast cells), cell products, molecules with immunosuppressive potential and immunotherapy.


Subject(s)
Cell- and Tissue-Based Therapy/methods , Conjunctivitis, Allergic/drug therapy , Conjunctivitis, Allergic/epidemiology , Histamine Antagonists/therapeutic use , Immunosuppression Therapy/methods , Mast Cell Stabilizers/therapeutic use , Adolescent , Child , Conjunctivitis, Allergic/diagnosis , Conjunctivitis, Allergic/immunology , Eye/immunology , Eye/pathology , Female , Humans , Incidence , Male , Prevalence , Quality of Life , Risk Factors , Treatment Outcome
5.
Acta Derm Venereol ; 100(10): adv00131, 2020 May 11.
Article in English | MEDLINE | ID: mdl-32250439

ABSTRACT

Isatis tinctoria L. (woad) has been used in medicine for centuries and has demonstrated anti-inflammatory effects. However, to date, no well-defined extracts with precise analysis of active substances have been developed. The aim of this study was to develop novel extracts of Isatis tinctoria L., and to characterize their active ingredients and anti-inflammatory properties. Various extracts of Isatis tinctoria L. were analysed for their active ingredients, and screened for anti-inflammatory effects using cyclooxygenase-2 activity assays. A petroleum ether extract was found to have the best effects, and was tested in a mouse model of acute allergic contact dermatitis. In the mouse model the petroleum ether extract resulted in significantly reduced ear swelling, oedema and inflammatory cell density. In mouse skin and human keratinocyte cultures, petroleum ether extract inhibited pro-inflammatory cytokine expression. Furthermore, human mast cell degranulation was significantly inhibited in LAD2 cell cultures. In conclusion, novel woad extracts were developed and shown to have anti-inflammatory properties in a contact hypersensitivity animal model and human keratinocytes. The production of such extracts and further characterization of their specific properties will enable determination of their potential dermatological effects in the treatment of inflamed and irritated skin.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Dermatitis, Allergic Contact/drug therapy , Isatis , Phytotherapy , Plant Extracts/therapeutic use , Administration, Topical , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/immunology , Cells, Cultured , Dermatitis, Allergic Contact/immunology , Dermatologic Agents/administration & dosage , Dermatologic Agents/immunology , Dermatologic Agents/therapeutic use , Disease Models, Animal , Ear , Humans , Interleukin-1beta/antagonists & inhibitors , Interleukin-1beta/immunology , Interleukin-33/antagonists & inhibitors , Interleukin-33/immunology , Interleukin-6/antagonists & inhibitors , Interleukin-6/immunology , Keratinocytes/drug effects , Keratinocytes/immunology , Mast Cell Stabilizers/administration & dosage , Mast Cell Stabilizers/immunology , Mast Cell Stabilizers/therapeutic use , Mast Cells/drug effects , Mast Cells/immunology , Mice , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Skin/drug effects , Skin/immunology , Skin/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...